Theratechnologies, Inc. (THTX) Social Stream

Featured Post From StockTwits About THTX

$THTX These are the 11 approved ADC’s also targeted drug delivery technology, I am going to bypass Mylotarg as the drug was approved first in 2000 but due to adverse effects it got black box warning later in 2010 it was withdrawn and in 2017 it was approved again and still has the warning.
Note the market sizes quoted below are for the cancers mentioned and not for late stages of them but I think it would be good to include them as a references.

Adcetris targeting Hodgkin lymphoma. The Non-Hodgkin Lymphoma Therapeutics market in the U.S. is estimated at $1.6 Billion in the year 2020 and systemic anaplastic large-cell lymphoma (rare condition with low prevalence), the drug is commercialized by Seattle Genetics (among others) now known as Seagen, approved in 2011.
They sold in 2021 $344.5M, 2020 $658.6M, 2019 $627.7M, 2018 $476.9M, 2017 $307.6M etc. so the sales of the drug has a decent growth rate YOY. Adcetris Costs $4,500 Per Vial, or over $100,000 for a course of Lymphoma treatment.